{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:42:26Z","timestamp":1760157746892,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210130"],"award-info":[{"award-number":["RP210130"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"crossref","award":["T32 HS 26133-5"],"award-info":[{"award-number":["T32 HS 26133-5"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Importance: Understanding trends in the use of hormonal therapy (HT) for prostate cancer (PCa) is crucial to optimize treatment strategies, particularly for older men with locally advanced and metastatic disease. Objective: To evaluate changes in the patterns of adjuvant and primary HT use over time in older U.S. men diagnosed with locally advanced and metastatic prostate cancer. Design, Setting, and Participants: This cohort study utilized SEER-Medicare data, which covers approximately 48% of the U.S. population and links cancer registry data with Medicare claims, including 149,515 men aged \u226566 years diagnosed with PCa between 2010 and 2019. We analyzed trends in the use of adjuvant HT for higher-risk and primary HT for lower-risk PCa. Multivariable logistic regression models were used to adjust for clinical and demographic factors. Main Outcomes and Measures: The primary outcome was the proportion of men receiving any form of HT within 6 months of PCa diagnosis. HT included injectable Gonadotropin-releasing hormone (GnRH) agonists and antagonists, orchiectomy, and anti-androgens agents. Results: The rate of adjuvant HT in higher-risk PCa patients increased significantly from 53.6% in 2010 to 68.1% in 2019 (p &lt; 0.0001), with a steady rise in the last four years. In contrast, the rate of men with lower-risk disease receiving primary HT declined from 25% in 2010 to 16.9% in 2013, then peaked at 28.2% in 2015, and stabilized between 25% and 27.3% from 2017 to 2019. The overall HT usage increased from 33.5% in 2010 to 45.2% in 2019, showing a consistent increase over the years. These patterns persisted after adjusting for clinical and demographic factors. Conclusions and Relevance: The increasing use of adjuvant HT in higher-risk PCa patients aligns with evolving treatment guidelines, while the stable rate of primary HT in lower-risk patients represents persistent inappropriate use and highlights the need for further efforts to optimize treatment choices. While previous studies focused on men with intermediate-risk PCa receiving radiation therapy, our study broadens the scope to include men who did not undergo radiation therapy, providing a more inclusive view of HT trends. Future research should focus on refining strategies to reduce inappropriate primary HT use and improve adjuvant HT administration.<\/jats:p>","DOI":"10.3390\/cancers17193231","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:42:49Z","timestamp":1759750969000},"page":"3231","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hormonal Therapy Patterns in Older Men with Prostate Cancer in the United States, 2010\u20132019"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-5294","authenticated-orcid":false,"given":"Mohanad","family":"Albayyaa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-0927","authenticated-orcid":false,"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahakn","family":"Shahinian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, MI 48104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, O\u2019Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"},{"name":"Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biai","family":"Digbeu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-2042","authenticated-orcid":false,"given":"Randall","family":"Urban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Baillargeon","sequence":"additional","affiliation":[{"name":"Department of Public Health, Robbins College of Health and Human Sciences, Baylor University, Waco, TX 76798, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"American Cancer Society (2020). Cancer Facts & Figures 2020, American Cancer Society."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate cancer, Version 1.2021","volume":"19","author":"Mohler","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effect of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_7","unstructured":"National Comprehensive Cancer Network (2020, March 05). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31","volume":"15","author":"Pilepich","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_10","unstructured":"American Urological Association (2020, March 05). Prostate Cancer: Clinically Localized Disease. Available online: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/clinically-localized-prostate-cancer-aua\/astro-guideline-2022."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.18.00606","article-title":"Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association\/American Society for Radiation Oncology\/Society of Urologic Oncology guideline","volume":"36","author":"Bekelman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"583","article-title":"NCCN Guidelines Updates: Management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/95.13.981","article-title":"National practice patterns and time trends in androgen ablation for localized prostate cancer","volume":"95","author":"Cooperberg","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_20","unstructured":"Medicare Payment Advisory Commission (2007). Report to the Congress: Effects of Medicare Payment Changes on Oncology Services."},{"key":"ref_21","first-page":"S29","article-title":"Update: NCCN prostate cancer clinical practice guidelines","volume":"3","author":"Scardino","year":"2005","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1200\/JCO.2006.09.9580","article-title":"Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer","volume":"25","author":"Shahinian","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_23","unstructured":"National Cancer Institute (2020, March 05). SEER-Medicare Linked Database, Available online: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/."},{"key":"ref_24","unstructured":"Centers for Medicare & Medicaid Services (2020, March 05). Medicare Coverage, Available online: https:\/\/www.medicare.gov\/what-medicare-covers."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ejca.2015.03.003","article-title":"Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study","volume":"51","author":"Chan","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer: American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"ref_30","unstructured":"SAS Institute Inc (2014). SAS\/STAT\u00ae 9.4 User\u2019s Guide, SAS Institute Inc."},{"key":"ref_31","unstructured":"(2025, September 24). University of Texas Medical Branch Institutional Review Board. Available online: https:\/\/www.utmb.edu\/provost\/resources\/research-regulations-and-compliance\/irb\/home."},{"key":"ref_32","unstructured":"European Association of Urology (2020, March 05). EAU Guidelines for Prostate Cancer. Available online: https:\/\/uroweb.org\/guideline\/prostate-cancer\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","article-title":"Prostate Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Mohler","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1200\/JOP.2016.020206","article-title":"Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D","volume":"13","author":"Caram","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: A population-based cohort study in Denmark (1999 to 2007)","volume":"184","author":"Jensen","year":"2010","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/OP.23.00040","article-title":"Disparities in diagnosis, treatment access, and time to treatment among Hispanic men with metastatic prostate cancer","volume":"19","author":"Hougen","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cncr.21732","article-title":"Racial Disparity and Socioeconomic Status in Association with Survival in Older Men with Localized Prostate Carcinoma","volume":"106","author":"Du","year":"2006","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100904","DOI":"10.1016\/j.adro.2022.100904","article-title":"Trends in androgen deprivation use in men with intermediate-risk prostate cancer who underwent radiation therapy","volume":"7","author":"Agrawal","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1200\/JCO.2013.52.5782","article-title":"Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer","volume":"32","author":"Potosky","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1464-410X.2011.10760.x","article-title":"Locally advanced prostate cancer: A population-based study of treatment patterns","volume":"109","author":"Lowrance","year":"2012","journal-title":"BJU Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): A randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): An open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy plus docetaxel versus ADT alone in metastatic non-castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","article-title":"Reimbursement policy and androgen-deprivation therapy for prostate cancer","volume":"363","author":"Shahinian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_53","first-page":"289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial","volume":"299","author":"Chen","year":"2008","journal-title":"JAMA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3231\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:19:06Z","timestamp":1760156346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":53,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193231"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193231","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,10,4]]}}}